Back to Search
Start Over
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
- Source :
- Molecular Oncology, Vol 16, Iss 14, Pp 2733-2746 (2022)
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
-
Abstract
- Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O6‐methylguanine‐DNA methyltransferase (MGMT) inactivation in advanced BTC patients is not established. We investigated the prevalence, prognostic, and predictive impact of MGMT inactivation in two multicenter cohorts. MGMT inactivation was assessed through PCR and immunohistochemistry (IHC) in an Italian cohort; the results were then externally validated using RNA sequencing (RNA‐seq) data from the BTC subcohort of the Molecularly Aided Stratification for Tumor Eradication Research (MASTER) precision oncology program of the National Center for Tumor Diseases Heidelberg and the German Cancer Consortium. Among 164 Italian cases, 18% presented MGMT promoter hypermethylation (> 14%) and 73% had negative MGMT protein expression. Both were associated with worse overall survival (OS; HR 2.31; P
Details
- Language :
- English
- ISSN :
- 18780261 and 15747891
- Volume :
- 16
- Issue :
- 14
- Database :
- Directory of Open Access Journals
- Journal :
- Molecular Oncology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.3b4516fdda224755a9583e4ef6af9f00
- Document Type :
- article
- Full Text :
- https://doi.org/10.1002/1878-0261.13256